Can a patient inject undiluted Kenalog (triamcinolone) into an active pimple?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 18, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Intralesional Triamcinolone for Active Acne Lesions

Yes, a patient can inject undiluted Kenalog (triamcinolone) 10 mg/mL into an active inflammatory acne papule or nodule, as this concentration is specifically recommended by the American Academy of Dermatology for nodular acne treatment. 1, 2, 3

Recommended Concentration and Dosing

  • The standard concentration for acne is triamcinolone acetonide 10 mg/mL, which can be used undiluted or diluted with sterile normal saline to 5 mg/mL or 3.3 mg/mL. 1, 2, 3

  • The injection volume should be 0.05-0.1 mL per lesion, producing a visible papule approximately 0.5 cm in diameter. 2, 3

  • Lower concentrations (2.5-5 mg/mL) are commonly used in clinical practice to minimize adverse effects, with 2.5 mg/mL being the most frequently reported concentration among dermatologists (52.5% of practitioners). 4

Proper Indications

This treatment is indicated specifically for:

  • Large, painful inflammatory nodules or cysts at risk for scarring 1, 2, 3
  • Occasional stubborn individual cystic lesions resistant to other therapies 2, 3
  • Situations requiring rapid reduction in inflammation and pain (48-72 hours) 2, 3

Critical limitation: This is an adjuvant therapy only, not effective for multiple lesions or as primary treatment. 1, 2, 3

Injection Technique

  • Inject intradermally into the center of the lesion - 61.6% of dermatologists inject into the center of the lesion. 4

  • Proper placement is confirmed by formation of a visible papule with blanching. 3

  • The injection depth should be just beneath the dermis in the upper subcutis, avoiding superficial injection which dramatically increases atrophy risk. 2

Adverse Effects and Risk Mitigation

Local complications occur but can be minimized:

  • Skin atrophy occurs in 44% of patients when using higher concentrations, but using 10 mg/mL or lower significantly reduces this risk. 2

  • When atrophy does occur, it typically lasts over 6 months (48.4% of cases). 4

  • Hypopigmentation, pigmentary changes, and telangiectasias can develop. 2, 3

To minimize adverse events:

  • Use the lowest effective concentration and volume - decreasing from 40 mg/mL to 10 mg/mL or diluting to 5 mg/mL significantly reduces atrophy risk. 2

  • Avoid injecting too superficially, which increases atrophy and pigmentary changes. 2

  • Apply sparingly to skin folds and intertriginous areas. 3

Contraindications

Do not inject if:

  • Active infection is present at the injection site 3
  • Patient has previous hypersensitivity to triamcinolone 3
  • Active tuberculosis or systemic fungal infection exists (for large injections) 3

Clinical Context

  • Most acne nodules flatten within 48-72 hours after injection. 2, 3

  • This treatment should be reserved for occasional or particularly stubborn cystic lesions, not used for multiple lesions. 2, 3

  • Patients with severe nodular acne, significant psychosocial burden, or scarring should be considered candidates for isotretinoin as definitive therapy rather than relying on repeated intralesional injections. 1, 3

  • Always use intralesional corticosteroids in conjunction with comprehensive topical therapy (retinoids, benzoyl peroxide) and systemic treatments when appropriate. 1, 3

Common Pitfalls to Avoid

  • Do not use this as primary treatment for multiple acne lesions - it is ineffective as monotherapy and increases adverse effect risk. 2, 5

  • Do not inject excessively or use concentrations higher than 10 mg/mL for acne - this dramatically increases adverse effect risk without improving efficacy. 2

  • Do not inject superficially - this increases atrophy and pigmentary changes. 2

  • Counsel patients on potential hypopigmentation and atrophy before injection - 50.5% of dermatologists do this routinely. 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Intralesional Corticosteroid Injections for Acne and Keloids

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Intralesional Triamcinolone for Acne Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Dermatologist Use of Intralesional Triamcinolone in the Treatment of Acne.

The Journal of clinical and aesthetic dermatology, 2020

Guideline

Treatment of Steroid Acne

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.